CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 358 enrolled
Drug / intervention
Omega-3 Fatty Acids (Fish Oil Supplements) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00729430
NCT00729430Phase 3Completed
CompareCT.gov

Prognostic, Anti-arrhythmic, and Ventricular Remodeling Effects of High Dose Fish Oil in Patients With a Recent Myocardial Infarction

Brigham and Women's Hospital·interventional·Posted Aug 7, 2008·Updated Jun 1, 2017

In Brief

A Phase 3 clinical trial evaluating Omega-3 Fatty Acids (Fish Oil Supplements) and Placebo for Myocardial Infarction and Death, Sudden, Cardiac. Completed, enrolled 358 participants across 1 site.

Detailed Summary

Doctors use magnetic resonance imaging (MRI) to obtain detailed pictures of the inside of the body. This study will evaluate a new MRI technique in people who have recently had a heart attack. Researchers will also examine the effect of fish oil supplementation on heart health in study participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction, Death, Sudden, Cardiac
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), GlaxoSmithKline

Timeline

Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 7, 2008
Enrollment StartAug 1, 2008
Primary CompletionOct 1, 2013
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 17.9 years ago

Interventions

Omega-3 Fatty Acids (Fish Oil Supplements)drug

4 grams of omega-3 fatty acids taken orally once per day for 6 months

Placebodrug

Placebo tablets taken orally once per day for 6 months